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Abstract: Indoleamine 2,3-dioxygenase 1 (IDO1) metabolizes L-tryptophan to 
kynurenines (KYN), inducing T-cell suppression either directly or by altering  
antigen-presenting-cell function. Cyclooxygenase (COX)-2, the rate-limiting enzyme in the 
synthesis of prostaglandins, is over-expressed by several tumours. We aimed at 
determining whether COX-2 inhibitors down-regulate the IFN--induced expression of 
IDO1 in acute myeloid leukaemia (AML) cells. IFN-γ at 100 ng/mL up-regulated COX-2 
and IDO1 in HL-60 AML cells, both at mRNA and protein level. The increased COX-2 
and IDO1 expression correlated with heightened production of prostaglandin (PG)E2 and 
kynurenines, respectively. Nimesulide, a preferential COX-2 inhibitor, down-regulated 
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IDO1 mRNA/protein and attenuated kynurenine synthesis, suggesting that overall  
IDO inhibition resulted both from reduced IDO1 gene transcription and from inhibited 
IDO1 catalytic activity. From a functional standpoint, IFN--challenged HL-60 cells 
promoted the in vitro conversion of allogeneic CD4+CD25− T cells into bona fide 
CD4+CD25+FoxP3+ regulatory T cells, an effect that was significantly reduced by 
treatment of IFN-γ-activated HL-60 cells with nimesulide. Overall, these data point to 
COX-2 inhibition as a potential strategy to be pursued with the aim at circumventing 
leukaemia-induced, IDO-mediated immune dysfunction. 
Keywords: indoleamine 2-3-dioxygenase; immune tolerance; acute leukaemia; regulatory 
T cells; immunotherapy; interferon-γ 
 
1. Introduction 
Indoleamine 2,3-dioxygenase 1 (IDO1) has become a recognized mediator of immune tolerance in 
cancer-bearing hosts, promoting local metabolic changes that affect cellular and systemic responses to 
inflammatory and immunological signals [1]. Tryptophan metabolism mediated by IDO1 generates 
biologically active kynurenine pathway metabolites, leading to differentiation and/or activation of 
FoxP3-expressing regulatory T cells (Treg), to suppression of anti-tumour T-cell responses and to 
reduced dendritic cell (DC) immunogenicity [2,3]. The rapid consumption of tryptophan from the local 
microenvironment triggers the activation of molecular stress-response pathways, such as those 
involving the GCN2 kinase [4], leading to cell cycle arrest and anergy in CD8+ T cells, and to 
regulatory T-cell (Treg) differentiation and inhibition of Th17 cytokine secretion in CD4+ T cells [1]. 
Constitutive expression of IDO is detected primarily at mucosal sites, but the IDO1 pathway is induced 
in many tissues during inflammation, as IDO1 gene expression is tightly regulated by interferon  
(IFN)-γ [5]. Early reports suggested that all 3 types of IFN (α,  and ) may induce IDO [6]. However, 
normal and transformed cell lines were shown to express IDO in response to IFN-, but not to IFN-α or 
IFN- [5]. When tested in vitro, lung fibroblasts and bladder carcinoma cell lines did not express IDO 
in response to either IFN-α or IFN- [7]. Similarly, IDO mRNA in human fibroblasts is induced by 
IFN-α but transiently and with lower potency when compared with IFN- [8]. 
IDO1 is also expressed by a variety of tumours [9] and by antigen-presenting cells (APC), including 
macrophages, human monocyte-derived DC, and individual subsets of murine DC [10,11]. IDO1 
activity in tumour cells may reflect either constitutive IDO1 protein expression [12] or IDO1 induction 
as a consequence of microenvironmental interactions [9]. In this respect, gastric carcinoma, colon 
carcinoma and renal cell carcinoma cell lines do not express IDO1 constitutively but rather they  
up-regulate the enzyme following IFN- stimulation [13]. Importantly, IDO1 confers an unfavourable 
prognosis to a variety of solid tumours and to acute myeloid leukaemia (AML) [14,15]. In patients 
with AML, a higher serum kynurenine/tryptophan ratio correlates with shorter survival [16]. Also, 
high IDO mRNA levels in blast cells of adult patients with AML predict a poor clinical outcome [14]. 
Prostaglandin (PG) G/H synthases, referred to as COX, exist in two isoforms, COX-1 and COX-2, 
and convert arachidonic acid into a biologically inactive unstable intermediate, the PGH2, which is 
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further converted by cell-specific synthases into biologically active end-products, collectively known 
as prostanoids [17]. Like IDO1, COX-2 can be induced by IFN- in several cell types [18]. 
Importantly, COX-2 is constitutively over-expressed by epithelial malignancies, including human  
non-small cell lung cancer, where it confers a malignant and metastatic phenotype [19]. This 
phenomenon is largely due to overproduction of PGE2, a prostanoid that enhances cell proliferation, 
invasion, metastasis and angiogenesis, and inhibits apoptosis [20–22]. Although the molecular 
mechanisms implicated in COX-2 up-regulation in leukaemia cells remain elusive, there is evidence 
that blast cells from at least some subsets of patients with AML express functional COX-2 in response 
to an array of stimuli [23]. The ability of COX-2 to promote escape from immunosurveillance is 
exemplified by the observation that inhibition of COX-2/PGE2 in mice with lung cancer reduces  
Treg-cell frequencies and increases the number of CXCR3+, anti-tumour effector T cells [24]. The 
interplay between COX-2 and IDO1 is further underpinned by studies in animal models of cancer, 
where pharmacological blockade of COX-2 translated into down-regulation of IDO1 expression at the 
tumour site, leading to decreased serum kynurenines [25,26]. It is presently unknown whether  
IFN--induced COX-2 may also regulate IDO1 expression in human leukaemia cells.  
2. Results and Discussion 
2.1. Induction of Functionally Active COX-2 and IDO1 by IFN- in HL-60 Cells 
IFN-γ signalling occurs through the JAK-STAT pathway, leading to the phosphorylation of STAT-1α 
and to its translocation to the nucleus, where it initiates transcription [27]. We first investigated 
whether HL-60 cells express receptors for IFN-. Cells were analyzed by flow cytometry after 
labelling with anti-CD119 monoclonal antibodies (mAb) that react against the IFN- receptor α chain, 
required for ligand binding and for signalling [28]. As shown in Figure 1A, HL-60 cells expressed 
readily detectable levels of CD119 antigen on the cell surface. HL-60 cells were then incubated with 
IFN-, a prototypical inducer of IDO in normal and tumour cell types [6], for up to 96 h. For 
polymerase chain reaction (PCR) studies, RNA was isolated, converted to cDNA and amplified for 
COX-2 and IDO1. Equivalence of RNA loading was verified by the consistency of mRNA 
housekeeping signals (data not shown). As illustrated in Figure 1B, COX-2 transcripts were detected 
within 24 h after incubation with IFN-γ, and steadily increased at 72 h and 96 h, in accordance with 
previous reports suggesting the ability of HL-60 cells to express COX-2 after culture with doxorubicin 
or with lipopolysaccharide [23,29]. Conversely, IDO1 mRNA was detected in HL-60 AML cells 48 h 
after IFN- provision, and remained stably expressed for up to 3 days. Changes in COX-2 expression 
after leukaemia cell stimulation with IFN-γ would be suggestive of the involvement of the COX-2 
system in IDO1 induction. To analyze the effects of IFN-γ on COX-2 and IDO1 expression and 
regulation, we performed western blot analyses using COX-2-specific and IDO1-specific antibodies. 
Not unexpectedly, blotting with an antibody specific to the transcriptionally active, phosphorylated 
form of STAT-1 showed that phospho-STAT-1 was rapidly induced by IFN-γ in leukaemia cells 
(Figure 1C). COX-2 protein was detected after 24 h of IFN-γ treatment, peaked at 72 h and declined 
thereafter (Figure 1C). IFN--treated HL-60 cells also expressed IDO1 protein, with maximum levels 
being detectable after 72 h from the addition of IFN-γ to the culture medium, as shown in Figure 1C. 
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The release of PGE2, a prostanoid that is dependent on COX-2 activity, was measured by ELISA, 
whereas kynurenine and tryptophan levels were quantified with RP-HPLC. Importantly, supernatants 
of IFN--treated HL-60 cells were significantly enriched both in PGE2 and in kynurenine compared 
with supernatants collected from cytokine-untreated cells and with culture medium alone (Figure 1D). 
In accordance with this finding, tryptophan was depleted in supernatants of IFN--stimulated HL-60 
cells (data not shown), pointing to the IDO-mediated activation of tryptophan metabolism. 
Collectively, these experiments indicated that COX-2 mRNA and protein are up-regulated by IFN-γ in 
leukaemia cells and that IFN- also induces functional IDO1 in HL-60 cells. 
Figure 1. Induction of COX-2 and IDO1 in HL-60 leukaemia cells. Panel A: The 
expression of IFN-γ receptor I (CD119) was investigated by flow cytometry. One 
representative experiment out of 4 with similar results is shown. Panel B: Quantitative  
RT-PCR was conducted to measure COX-2 and IDO1 mRNA levels in IFN-γ challenged 
HL-60 leukaemia cells. Graphs summarize 5 independent experiments. Data are expressed 
in terms of mean ± SEM. Panel C: HL-60 cells were activated with 100 ng/mL IFN-γ for 
up to 96 h, followed by Western blot runs to detect phosphorylated STAT1, COX-2 and 
IDO1 proteins. Panel D: Measurement of PGE2 and kynurenines in supernatants of HL-60 
leukaemia cells stimulated with 100 ng/mL IFN-γ. Bars reflect the mean and SEM 
recorded in 3 independent experiments. 
 
2.2. COX-2 Inhibition Restrains IDO1 Activity in AML Cells 
We next cultured HL-60 AML cells with nimesulide, a preferential COX-2 inhibitor, after their 
challenge with IFN-γ for 72 h. As shown in Figure 2A, nimesulide almost completely abrogated 
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kynurenine release by IFN-γ-activated AML cells. In line with these results, tryptophan was 
significantly depleted from the supernatant of AML cell cultures containing IFN-γ. BCH is a synthetic 
aminoacid that inhibits tryptophan influx through the system L transporter, which mediates a limiting 
step for IDO1-activated L-tryptophan degradation in placental tissues [30]. When added to HL-60 cells 
at 2 mM, a concentration that, by itself, has not been reported to affect significantly IDO enzymatic 
activity [27], BCH exerted but minimal effects on kynurenine release by IFN-γ-activated AML cells 
(Figure 2B).  
Figure 2. Modulation of IDO1 activity by COX-2 inhibitors. Leukaemia cells were 
stimulated with 100 ng/ml IFN-γ for 72 h, followed by the exposure to 100 µM nimesulide 
(NIM) for 24 h. Panel A: Kynurenine and tryptophan in culture supernatants (mean and 
SEM from 7 independent experiments). Panel B: Kynurenine levels after the provision of 
either nimesulide (NIM) or BCH, an inhibitor of amino acid transport, to leukaemia cells 
(mean and SEM from 3 independent experiments). * Denotes a p value < 0.01 compared 
with cultures maintained without nimesulide. Panel C: Kynurenine levels after 
simultaneous or sequential provision of IFN-γ and NIM to leukaemia cells. Panel D: PGE2 
levels after provision of NIM to IFN-γ-challenged leukaemia cells. Bars reflect the mean 
and SEM recorded in 3 independent experiments. * Denotes a p value < 0.01 compared 
with cultures maintained without nimesulide. Panel E: Kynurenine release after the 
provision of selective COX-2 (NS398) or COX-1 inhibitors (SC560, sulindac sulfide) to 
leukaemia cells. Bars reflect the mean and SEM recorded in 3 independent experiments.  
 
  
Molecules 2013, 18 10137 
 
 
Importantly, nimesulide also inhibited IDO-mediated tryptophan breakdown in cultures containing 
BCH, suggesting that nimesulide affected IDO1 catalytic activity rather than limiting substrate 
availability. We also measured kynurenine levels in cultures performed with AML cells that were 
either concurrently treated with IFN-γ and nimesulide for 96 h or sequentially exposed to IFN-γ for 72 h 
followed by further 24 h of culture with nimesulide. Figure 2C summarizes the results of these 
experiments by showing that simultaneous provision of nimesulide and IFN-γ to AML cells translated 
into an even more remarkable inhibition of IDO1 enzymatic activity compared with cultures that were 
first treated with IFN-γ to induce IDO1 and then incubated with nimesulide to inhibit COX-2. Nimesulide 
also down-regulated PGE2 release in supernatants of AML cells compared with IFN-γ-stimulated 
AML cells that were maintained in the absence of COX-2 inhibitors (Figure 2D).  
In a further set of experiments, we treated IFN-γ-stimulated AML cells with NS398, a selective and 
potent COX-2 inhibitor. Control cultures contained either SC560 or sulindac sulfide, which 
preferentially inhibit COX-1 activity. Sulindac sulfone, another metabolite of sulindac sulfoxide that 
has anticancer properties but lacks COX inhibitory activity, was used in selected experiments. As 
shown in Figure 2E, the provision of NS398 to IFN-γ-stimulated AML cells translated into a 
significant reduction of kynurenine levels in culture supernatants. In sharp contrast, COX-1 inhibitors 
only marginally affected kynurenine levels. As expected based on lack of COX inhibitory activity, sulindac 
sulfone had no measurable impact on the IFN-γ-induced release of kynurenine in culture supernatants. 
2.3. COX-2 Inhibition Regulates IDO1 Expression in AML Cells Both at Transcriptional and  
Post-Transcriptional Level 
It has been shown that treatment of tumour-bearing PyV MT mice with celecoxib, a selective COX-2 
inhibitor, reduces IDO protein levels and augments the efficacy of DC-based breast cancer vaccines [26]. 
In a further set of experiments, we aimed at addressing whether COX-2 may regulate IDO1 expression 
at either the mRNA or protein level. We used quantitative RT-PCR to measure IDO1 mRNA in  
IFN-γ-challenged leukaemia cells. As Figure 3A–C show, nimesulide significantly down-regulated 
IDO mRNA and protein in HL-60 AML cells. To assess whether IDO1 regulation by nimesulide 
occurred as a result of reduced COX-2 expression, HL-60 cells were initially activated with IFN-γ in 
the presence or absence of nimesulide, and then subjected to Western blot runs with COX-2- specific 
antibodies. Interestingly, COX-2 protein levels were unchanged in nimesulide-treated, IFN-γ-activated 
HL-60 cells compared with cultures maintained with IFN-γ alone, suggesting lack of modulation of 
COX-2 protein levels by the COX-2 inhibitor (Figure 3D). Recently, reduced intra-tumour expression 
of IDO and lowered PGE2 serum levels have been detected in mice with syngeneic lung cancer that 
were given COX-2 inhibitors [31]. Along the same line of research, it has been elegantly shown that 
mice with pancreatic adenocarcinoma treated with anti-tumour vaccines and celecoxib experience 
reduced COX-2 and IDO1 function, as manifested by lowered serum levels of PGE2 and kynurenine, 
respectively [25]. Taken together with the above mentioned in vivo studies, our findings point to the 
relevance of COX-2-mediated regulation of IDO1 expression in tumour cells at both transcriptional 
and post-transcriptional level. 
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Figure 3. Modulation of IDO1 mRNA and protein by COX-2 inhibitors. Leukaemia cells 
were stimulated with 100 ng/mL IFN-γ for 72 h, followed by the exposure to COX-2 
inhibitors for 24 h. Panel A: IDO mRNA expression by leukaemia HL-60 cells as assessed 
with quantitative RT-PCR. Panel B: IDO protein expression by leukaemia HL-60 cells in a 
representative experiment out of five with similar results. Panel C: Densitometry of 
western blot runs; bars depict the mean and SEM from five independent experiments. 
Culture conditions and lane numbers for the experiments shown in panels B and C are 
detailed at the bottom of panel B. Panel D: COX-2 and IDO protein expression by 
leukaemia HL-60 cells that were stimulated with IFN-γ and then treated with nimesulide 
for 24 h. A representative experiment out of 3 with similar results is shown.  
 
2.4. COX-2 Inhibition Restrains the in Vitro Generation of Bona fide Treg Cells by IFN--Stimulated 
HL-60 Cells 
FoxP3 is a transcription factor and master regulatory of Treg differentiation and function [32]. 
Moreover, the frequency of FoxP3+ Treg cells is increased in most tumours [33] and has been 
correlated with COX-2 activity in solid cancers [34]. We then asked whether COX-2 inhibition exerted 
any appreciable effect on the in vitro differentiation of Treg cells from naive T cells by IDO-expressing 
HL-60 AML cells. To this end, HL-60 cells were stimulated with exogenous IFN-γ for 72 h, followed 
by 24 h of culture with either nimesulide or PBS as a control culture condition. HL-60 were then plated 
with allogeneic CD4+CD25− T cells for 5 days in a mixed tumour- lymphocyte culture (MTLC). As 
shown in Figure 4A, IFN-γ-challenged HL-60 cells promoted the in vitro conversion of naive CD4+ T 
cells into bona fide Treg cells, an effect that was potentiated by the provision of IL-2, a Treg growth 
factor [35]. Interestingly, the frequency of FoxP3-expressing T cells was significantly lower in MTLC 
performed with HL-60 that were treated with nimesulide during IFN-γ challenge. A representative 
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experiment out of 3 with similar results is shown in Figure 4B. When providing the MTLC with HL-60 
leukaemia cells that were previously treated with NS398, Treg differentiation was also inhibited, at 
variance with co-cultures containing AML cells that were maintained with preferential COX-1 
inhibitors, such as SC560, or with sulfone sulfide. The cumulative data from this set of experiments is 
summarized in Figure 4C. It should be emphasized that the inhibition of Treg differentiation by HL-60 
cells pre-treated with nimesulide was not maximal, at variance with that attained with 1MT, a chemical 
IDO inhibitor currently in phase I clinical trials for patients with advanced cancer [36]. This 
interpretation of the data implies that both IDO1 and COX-2 activities may be required to promote 
Treg development by HL-60 leukaemia cells. Collectively, cellular assays suggested that COX-2 
inhibition interferes, albeit incompletely, with the in vitro generation of Treg cells by leukaemia cells. 
The favourable effects of constrained Treg expansion on the anti-leukaemia immune response have 
been unravelled in immune-competent mice bearing A20 leukaemia, where IDO1 inhibitors were 
shown to promote disease control [37]. 
Figure 4. Effect of COX-2 inhibitors on leukaemia cell-induced differentiation of bona 
fide Treg cells. HL-60 cells were stimulated with 100 ng/mL IFN-γ for 72 h, followed by 
co-culture with allogeneic naive CD4+CD25− T cells for 5 days in a mixed tumour-
lymphocyte culture (MTLC). Panel A: Expression of CD25 and intracellular FoxP3 after 
co-culture with HL-60 AML cells in a representative experiment. IL-2 was provided to the 
cultures as a Treg-specific growth factor. Panel B: Expression of intracellular FoxP3 by 
CD4+ T cells after co-culture with HL-60 AML cells either in the absence or presence of 
100 mM nimesulide (one representative experiment is shown). Panel C: Cumulative results 
of co-culture experiments (n = 5), depicting the inhibition of Treg differentiation by AML 
cells that were also cultured with selective COX-2 (NS398) or COX-1 inhibitors (SC560, 
sulindac sulfide). In selected experiments, 1MT, a chemical inhibitor of IDO, was added at 
200 μM (final concentration) during the MTLC. Bars depict mean and SEM.  
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3. Experimental  
3.1. Cells and Reagents 
HL-60 AML cells were obtained from American Type Culture Collection (No CCL-240, ATCC, 
Manassas, VA, USA). IFN- was obtained from R&D Systems, Oxon, Cambridge, UK. The following 
antibodies were used: mouse monoclonal antibodies (mAb) against anti-IDO (clone 10.1; Millipore, 
Billerica, MA, USA), mouse mAb against COX-2, rabbit polyclonal anti-p-STAT-1(Tyr701) 
antibodies and mouse mAb against β-actin (Santa Cruz Biotechnology, Heidelberg, Germany).  
2-Amino-2-norbornanecarboxylic acid (BCH), an amino acid transport inhibitor (2 mM final 
concentration) and nimesulide (100 µM final concentration) were purchased from Sigma Chemical Co. 
(St. Louis, MO, USA). The following compounds were obtained from Merck Chemicals Ltd. 
(Nottingham, UK): SC-560 [5-(4-Chlorophenyl)-1-(4-methoxyphenyl)-3-trifluoromethylpyrazole], 
sulindac sulfide (a metabolite of the nonsteroidal anti-inflammatory drug sulindac sulfoxide and a  
cell-permeable selective COX-1 inhibitor), and NS-398 [N-(2-Cyclohexyloxy-4-nitrophenyl)-
methanesulfonamide, a cell-permeable selective COX-2 inhibitor]. Sulindac sulfone, a cell-permeable 
sulfone metabolite of sulindac sulfoxide which lacks COX inhibitory activity (Merck Chemicals Ltd.), 
was used in control experiments. Each COX inhibitor drug was used at a concentration 10 times higher 
than the IC50 value reported by the manufacturer. 
3.2. Induction of IDO1 in Leukaemia HL-60 Cells 
HL-60 AML cells were maintained in culture with Iscove’s Modified Dulbecco’s Medium (IMDM; 
Life Technologies BRL, Rockville, MD, USA) supplemented with 20% foetal bovine serum (FBS), 
penicillin-streptomycin (EuroClone, Milan, Italy) and 2 mM L-glutamine (Life Technologies). Cells 
were grown in 25 cm2 culture flasks (Corning, Corning, NY, USA) at 37 °C in a 5% CO2 humidified 
atmosphere, and cell density was maintained at 1 × 105–106 viable cells by replacing medium every  
2–3 days. HL-60 cells were exposed to exogenous IFN- for up to 96 h. After culturing, cells were 
recovered, counted and subjected to quantitative real-time (RT)-PCR for the detection of COX-2 and 
IDO1 mRNA or to western blotting experiments, as detailed below. For COX-2 inhibition, HL-60 cells 
(1 × 105/mL) were stimulated for 72 h with 100 ng/mL recombinant human IFN-γ and then treated for 
24 h with either of the following reagents: 100 µM nimesulide, 50 µM NS-398, 50 µM sulindac 
sulfide, 50 µM sulindac sulfone or DMSO (solvent). Cell viability after treatment with inhibitors was 
estimated with trypan blue exclusion dye (EuroClone). 
3.3. T-Cell Isolation and Primary MLR 
Mononuclear cells from healthy consented subjects were isolated by Ficoll-Hypaque density 
gradient, as previously published [38]. CD25+ cells were purified by positive selection using directly 
conjugated anti-CD25 magnetic microbeads (4 μL per 107 cells; Miltenyi Biotec, Bergisch Gladbach, 
Germany). After the double column procedure, CD4+CD25+ cells were routinely more than 94% pure 
by FACS analysis (data not shown). The remaining non-CD25+ fraction was used for the isolation of 
CD4+CD25− cells by positive selection with anti-CD4 mAb-coated microbeads (Miltenyi Biotec). 
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CD4+CD25− T cells were cultivated with HL-60 AML cells in mixed lymphocyte-tumour  
cultures (MLTC). 
3.4. Immunological Markers and Flow Cytometry 
Cells were incubated for 20 min at 4 °C with fluorochrome-conjugated anti-CD4, anti-CD25 and 
anti-CD119 mAb (all from BD Biosciences, Mountain View, CA, USA) or with fluorochrome-conjugated, 
isotype-matched irrelevant mAb to establish background fluorescence. The frequency of bona fide 
Treg cells was determined with the Human Regulatory T-Cell Staining Kit (eBioscience, San Diego, 
CA, USA). Briefly, cells were initially labelled with anti-CD4 and anti-CD25 mAb, followed by 
sequential fixation and permeabilization, and by staining with Alexa Fluor 488-conjugated anti-FoxP3 
mAb (PCH101 clone). All samples were run through a FACS Canto® II flow cytometer  
(BD Biosciences) with standard equipment, as already detailed [11]. 
3.5. Measurement of PGE2 by ELISA 
PGE2 levels in culture supernatants were measured with a commercially available ELISA kit (R&D 
Systems). The minimum detectable dose of PGE2, as evaluated by the manufacturer, ranges between 
18.2 and 36.8 pg/mL. 
3.6. Western Blotting 
After treatment with IFN-γ, 1 × 106 HL-60 cells were re-suspended with PBS and centrifuged at 
1,200 rpm for 10 min. Cell pellets were lysed with RIPA buffer and protease inhibitors (Sigma 
Chemicals). Cell lysates were incubated for 5 minutes on ice, and then clarified by centrifugation at 
13,000 rpm for 20 min. Once obtained, cell extracts were boiled for 5 min at 95 °C and total lysate  
(40 µg) was analyzed by 10% sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE). 
Samples were then transferred onto a nitrocellulose membrane (Amersham Hybond; GE Healthcare, 
Milan, Italy). After blocking non-specific binding, blots were probed overnight at 4 °C with either 
primary mouse mAb directed against IDO (2 µg/mL) or COX-2 (1:100 dilution), or rabbit polyclonal 
anti-p-STAT-1(Tyr701) (1:200 dilution) or mouse mAb directed against β-actin (1:2,000 dilution). The 
membrane was then incubated with horseradish peroxidase-conjugated rabbit or mouse secondary 
antibodies (Sigma) as appropriate, and the chemiluminescence reaction was detected with Amersham 
ECL-western blotting detection reagents (GE Healthcare). Densitometry was performed by quantifying 
the bands with a freely available image analysis tool written at the National Institutes of Health (Scion 
Image for Windows 4.03). 
3.7. Quantitative RT-PCR 
Total RNA was extracted from HL-60 cells using the RNeasy mini kit (Qiagen, Milan, Italy), 
according to the manufacturer’s instructions. Complementary DNA (cDNA) was prepared starting 
from 1 µg of total RNA using Moloney Murine Leukemia Virus (MMLV) reverse transcriptase and 
random hexamer primers (Promega, Milan, Italy). Gene expression levels were quantified by a SYBR 
Green-based real-time method. Reactions were carried out in triplicate in a final volume of 25 µL 
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containing 2 µL of cDNA, iQ SYBR Green Supermix (2×) (Bio-Rad Laboratories, Milan, Italy) and 
250 nM of each primer. Amplifications were carried out using specific primers for the IDO1 gene 
(forward primer 5'-3' GGTCATGGAGATGTCCGTAA; reverse primer 5'-3' ACCAATAGAGAGAC 
CAGGAAGAA) or the COX2 gene (forward primer 5'-3' CCTGCCCTTCTGGTAGAAA; reverse 
primer 5'-3' GGACAGCCCTTCACGTTATT). GAPDH served as a housekeeping gene (forward 
primer 5'-3': TCCCTGAGCTGAACGGGAAG; reverse primer 5'-3': GGAGGAGTGGGTGTCGTCG 
CTGT). Thermal cycling was performed with the iCycler iQ system (Bio-Rad Laboratories) using 60 °C 
as annealing temperature. All quantifications were normalized to the reference gene and expressed 
using the ΔCt method. 
3.8. IDO1 Activity 
Tryptophan and kynurenine levels were measured with reverse-phase (RP)-HPLC. Briefly, sample 
aliquots were deproteinized with 0.3 M HClO4. Supernatants were spiked with 50 µM  
3-L-nitrotyrosine and analyzed using a ReproSil-Pur C18-AQ RP-HPLC column (Dr. Maisch GmbH, 
Ammerbuch-Entringen, Germany), using a double-pump HPLC apparatus from Jasco (Tokyo, Japan) 
equipped with spectrophotometric and fluorescence detectors. The chromatographic peaks were 
detected by recording UV absorbance at 360 nm and emission fluorescence at 366 nm, after excitation 
at 286 nm. The elution solvent was as follows: 2.7% CH3CN in 15 mM acetate buffer, pH 4.0 (both 
HPLC-grade; Fluka, Milan, Italy). The Borwin 1.5 and MS Excel software packages were used for 
instrument set-up and peak quantification. The concentration of components was calculated according 
to peak heights and was compared both with 3-nitro-L-tyrosine as internal standard and with reference 
curves constructed with L-tryptophan and kynurenine. 
3.9. Statistical Analysis 
The approximation of data distribution to normality was preliminarily tested with statistics for 
kurtosis and symmetry. Results were presented as mean and SD. All comparisons were performed with 
the Student’s t test for paired or unpaired determinations or with the analysis of variance (ANOVA), as 
appropriate. The criterion for statistical significance was defined as p ≤ 0.05. 
4. Conclusions 
The interactions between AML cells and the immune system contribute to the establishment of 
immune tolerance against malignant cells [39]. The present study suggests that the regulation of IDO1 
expression by inhibition of the COX-2/PGE2 pathway may constrain the leukaemia-induced immune 
suppression. It has been demonstrated that blasts from some patients with AML have the ability to  
up-regulate COX-2 expression in response to pro-inflammatory stimuli [23]. Conceivably, chronic 
inflammation associated with cancer may create immune suppression through the up-regulation of 
IDO1, but locally in the bone marrow microenvironment and systemically [40,41]. Our findings thus 
portend favourable implications for immunotherapy trials aimed at reinstituting anti-leukaemia 
immune responses through the inhibition of the COX-2/IDO1 axis. 
  
Molecules 2013, 18 10143 
 
 
Acknowledgments 
The present study has been supported by research grants from AIRC (“5 × 1000 Special Grant” to F.L.) 
and MIUR (PRIN-2009 to S.R.). 
Conflicts of Interest 
The authors declare no conflict of interest. 
References  
1. Munn, D.H.; Mellor, A.L. Indoleamine 2,3 dioxygenase and metabolic control of immune 
responses. Trends Immunol. 2013, 34, 137–143. 
2. Mellor, A.L.; Munn, D.H. IDO expression by dendritic cells: Tolerance and tryptophan 
catabolism. Nat. Rev. Immunol. 2004, 4, 762–774. 
3. Muller, A.J.; DuHadaway, J.B.; Donover, P.S.; Sutanto-Ward, E.; Prendergast, G.C. Inhibition of 
indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, 
potentiates cancer chemotherapy. Nat. Med. 2005, 11, 312–319. 
4. Munn, D.H.; Sharma, M.D.; Baban, B.; Harding, H.P.; Zhang, Y.; Ron, D.; Mellor, A.L. GCN2 
kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 
2,3-dioxygenase. Immunity 2005, 22, 633–642. 
5. Takikawa, O.; Kuroiwa, T.; Yamazaki, F.; Kido, R. Mechanism of interferon- action. 
Characterization of indoleamine 2,3-dioxygenase in cultured human cells induced by interferon- 
and evaluation of the enzyme-mediated tryptophan degradation in its anticellular activity.  
J. Biol. Chem. 1988, 263, 2041–2048. 
6. Taylor, M.W.; Feng, G.S. Relationship between interferon-, indoleamine 2,3-dioxygenase, and 
tryptophan catabolism. FASEB J. 1991, 5, 2516–2522. 
7. Byrne, G.I.; Lehmann, L.K.; Kirschbaum, J.G.; Borden, E.C.; Lee, C.M.; Brown, R.R. Induction 
of tryptophan degradation in vitro and in vivo: a -interferon-stimulated activity. J. Interferon Res. 
1986, 6, 389–396. 
8. Caplen, H.S.; Gupta, S.L. Differential regulation of a cellular gene by human interferon- and 
interferon-. J. Biol. Chem. 1988, 263, 332–339. 
9. Bonanno, G.; Mariotti, A.; Procoli, A.; Folgiero, V.; Natale, D.; De Rosa, L.; Majolino, I.; 
Novarese, L.; Rocci, A.; Gambella, M.; et al. Indoleamine 2,3-dioxygenase 1 (IDO1) activity 
correlates with immune system abnormalities in multiple myeloma. J. Transl. Med. 2012, 10, 247. 
10. Munn, D.H.; Sharma, M.D.; Hou, D.; Baban, B.; Lee, J.R.; Antonia, S.J.; Messina, J.L.; Chandler, P.; 
Koni, P.A.; Mellor, A.L. Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic 
cells in tumor-draining lymph nodes. J. Clin. Invest. 2004, 114, 280–290. 
11. Rutella, S.; Bonanno, G.; Procoli, A.; Mariotti, A.; de Ritis, D.G.; Curti, A.; Danese, S.;  
Pessina, G.; Pandolfi, S.; Natoni, F.; et al. Hepatocyte growth factor favors monocyte 
differentiation into regulatory interleukin (IL)-10++IL-12l°w/neg accessory cells with dendritic-cell 
features. Blood 2006, 108, 218–227. 
Molecules 2013, 18 10144 
 
 
12. Curti, A.; Aluigi, M.; Pandolfi, S.; Ferri, E.; Isidori, A.; Salvestrini, V.; Durelli, I.; Horenstein, A.L.; 
Fiore, F.; Massaia, M.; et al. Acute myeloid leukemia cells constitutively express the 
immunoregulatory enzyme indoleamine 2,3-dioxygenase. Leukemia 2007, 21, 353–355. 
13. Witkiewicz, A.; Williams, T.; Cozzitorto, J.; Durkan, B.; Showalter, S.; Yeo, C.J.; Brody, J.R. 
Expression of indoleamine 2,3-dioxygenase in metastatic pancreatic ductal adenocarcinoma 
recruits regulatory T cells to avoid immune detection. J. Am. Coll. Surg. 2008, 206, 849–854. 
14. Chamuleau, M.E.; van de Loosdrecht, A.A.; Hess, C.J.; Janssen, J.J.; Zevenbergen, A.; Delwel, R.; 
Valk, P.J.; Lowenberg, B.; Ossenkoppele, G.J. High INDO (indoleamine 2,3-dioxygenase) 
mRNA level in blasts of acute myeloid leukemic patients predicts poor clinical outcome. 
Haematologica 2008, 93, 1894–1898. 
15. Uyttenhove, C.; Pilotte, L.; Theate, I.; Stroobant, V.; Colau, D.; Parmentier, N.; Boon, T.;  
Van den Eynde, B.J. Evidence for a tumoral immune resistance mechanism based on tryptophan 
degradation by indoleamine 2,3-dioxygenase. Nat. Med. 2003, 9, 1269–1274. 
16. Corm, S.; Berthon, C.; Imbenotte, M.; Biggio, V.; Lhermitte, M.; Dupont, C.; Briche, I.; Quesnel, B. 
Indoleamine 2,3-dioxygenase activity of acute myeloid leukemia cells can be measured from 
patients' sera by HPLC and is inducible by IFN-. Leuk. Res. 2009, 33, 490–494. 
17. Rocca, B.; FitzGerald, G.A. Cyclooxygenases and prostaglandins: shaping up the immune 
response. Int. Immunopharmacol. 2002, 2, 603–630. 
18. Cesario, A.; Rocca, B.; Rutella, S. The interplay between indoleamine 2,3-dioxygenase 1 (IDO1) 
and cyclooxygenase (COX)-2 in chronic inflammation and cancer. Curr. Med. Chem. 2011, 18, 
2263–2271. 
19. Nakanishi, M.; Menoret, A.; Tanaka, T.; Miyamoto, S.; Montrose, D.C.; Vella, A.T.;  
Rosenberg, D.W. Selective PGE(2) suppression inhibits colon carcinogenesis and modifies local 
mucosal immunity. Cancer Prev. Res. 2011, 4, 1198–1208. 
20. Wang, D.; Dubois, R.N. Eicosanoids and cancer. Nat. Rev. Cancer 2010, 10, 181–193. 
21. Wang, D.; Dubois, R.N. The role of COX-2 in intestinal inflammation and colorectal cancer. 
Oncogene 2010, 29, 781–788. 
22. Wu, T. Cyclooxygenase-2 and prostaglandin signaling in cholangiocarcinoma. Biochim. Biophys. 
Acta 2005, 1755, 135–150. 
23. Vincent, C.; Donnard, M.; Bordessoule, D.; Turlure, P.; Trimoreau, F.; Denizot, Y. Cyclooxygenase-2 
(Cox-2) and blast cells of patients with acute leukemia. Leuk. Res. 2008, 32, 671–673. 
24. Sharma, S.; Yang, S.C.; Zhu, L.; Reckamp, K.; Gardner, B.; Baratelli, F.; Huang, M.; Batra, R.K.; 
Dubinett, S.M. Tumor cyclooxygenase-2/prostaglandin E2-dependent promotion of FOXP3 expression 
and CD4+CD25+ T regulatory cell activities in lung cancer. Cancer Res. 2005, 65, 5211–5220. 
25. Mukherjee, P.; Basu, G.D.; Tinder, T.L.; Subramani, D.B.; Bradley, J.M.; Arefayene, M.; Skaar, T.; 
De Petris, G. Progression of pancreatic adenocarcinoma is significantly impeded with a 
combination of vaccine and COX-2 inhibition. J. Immunol. 2009, 182, 216–224. 
26. Basu, G.D.; Tinder, T.L.; Bradley, J.M.; Tu, T.; Hattrup, C.L.; Pockaj, B.A.; Mukherjee, P. 
Cyclooxygenase-2 inhibitor enhances the efficacy of a breast cancer vaccine: role of IDO.  
J. Immunol. 2006, 177, 2391–2402. 
27. Platanias, L.C. Mechanisms of type-I- and type-II-interferon-mediated signalling. Nat. Rev. Immunol. 
2005, 5, 375–386. 
Molecules 2013, 18 10145 
 
 
28. Zaidi, M.R.; Merlino, G. The two faces of interferon- in cancer. Clin. Cancer Res. 2011, 17, 
6118–6124. 
29. Puhlmann, U.; Ziemann, C.; Ruedell, G.; Vorwerk, H.; Schaefer, D.; Langebrake, C.; 
Schuermann, P.; Creutzig, U.; Reinhardt, D. Impact of the cyclooxygenase system on 
doxorubicin-induced functional multidrug resistance 1 overexpression and doxorubicin sensitivity 
in acute myeloid leukemic HL-60 cells. J. Pharmacol. Exp. Ther. 2005, 312, 346–354. 
30. Kudo, Y.; Boyd, C.A. The role of L-tryptophan transport in L-tryptophan degradation by 
indoleamine 2,3-dioxygenase in human placental explants. J. Physiol. 2001, 531, 417–423. 
31. Lee, S.Y.; Choi, H.K.; Lee, K.J.; Jung, J.Y.; Hur, G.Y.; Jung, K.H.; Kim, J.H.; Shin, C.;  
Shim, J.J.; In, K.H.; et al. The immune tolerance of cancer is mediated by IDO that is inhibited by 
COX-2 inhibitors through regulatory T cells. J. Immunother. 2009, 32, 22–28. 
32. Hori, S.; Nomura, T.; Sakaguchi, S. Control of regulatory T cell development by the transcription 
factor Foxp3. Science 2003, 299, 1057–1061. 
33. Beyer, M.; Schultze, J.L. Regulatory T cells in cancer. Blood 2006, 108, 804–811. 
34. Shimizu, K.; Nakata, M.; Hirami, Y.; Yukawa, T.; Maeda, A.; Tanemoto, K. Tumor-infiltrating 
Foxp3+ regulatory T cells are correlated with cyclooxygenase-2 expression and are associated 
with recurrence in resected non-small cell lung cancer. J. Thorac. Oncol. 2010, 5, 585–590. 
35. Malek, T.R.; Bayer, A.L. Tolerance, not immunity, crucially depends on IL-2. Nat. Rev. Immunol. 
2004, 4, 665–674. 
36. Soliman, H.H.; Antonia, S.J.; Sullivan, D.; Vanahanian, N.; Link, C. Overcoming tumor antigen 
anergy in human malignancies using the novel indoleamine 2,3-dioxygenase (IDO) enzyme 
inhibitor, 1-methyl-D-tryptophan (1MT). J. Clin. Oncol. 2009, 27, 3004A. 
37. Curti, A.; Pandolfi, S.; Valzasina, B.; Aluigi, M.; Isidori, A.; Ferri, E.; Salvestrini, V.; Bonanno, G.; 
Rutella, S.; Durelli, I.; et al. Modulation of tryptophan catabolism by human leukemic cells results 
in the conversion of CD25− into CD25+ T regulatory cells. Blood 2007, 109, 2871–2877. 
38. Rutella, S.; Pierelli, L.; Bonanno, G.; Sica, S.; Ameglio, F.; Capoluongo, E.; Mariotti, A.; 
Scambia, G.; d'Onofrio, G.; Leone, G. Role for granulocyte colony-stimulating factor in the 
generation of human T regulatory type 1 cells. Blood 2002, 100, 2562–2571. 
39. Ustun, C.; Miller, J.S.; Munn, D.H.; Weisdorf, D.J.; Blazar, B.R. Regulatory T cells in acute 
myelogenous leukemia: is it time for immunomodulation? Blood 2011, 118, 5084–5095. 
40. Prendergast, G.C.; Chang, M.Y.; Mandik-Nayak, L.; Metz, R.; Muller, A.J. Indoleamine  
2,3-dioxygenase as a modifier of pathogenic inflammation in cancer and other inflammation-
associated diseases. Curr. Med. Chem. 2011, 18, 2257–2262. 
41. Muller, A.J.; Sharma, M.D.; Chandler, P.R.; Duhadaway, J.B.; Everhart, M.E.; Johnson, B.A., 3rd; 
Kahler, D.J.; Pihkala, J.; Soler, A.P.; Munn, D.H.; et al. Chronic inflammation that facilitates 
tumor progression creates local immune suppression by inducing indoleamine 2,3 dioxygenase. 
Proc. Natl. Acad. Sci. USA 2008, 105, 17073–17078. 
Sample Availability: Samples of the AML cell lines are available from the authors. 
© 2013 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article 
distributed under the terms and conditions of the Creative Commons Attribution license 
(http://creativecommons.org/licenses/by/3.0/). 
